These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 17973207)
1. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice. Mysliwiec J; Zbucki R; Winnicka MM; Sawicki B; Nikolajuk A; Kaminski K; Mysliwiec P; Musial W; Bondyra Z; Walecki J; Gorska M Horm Metab Res; 2007 Dec; 39(12):884-8. PubMed ID: 17973207 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 is not essential for bone turnover in hypothyroid mice. Mysliwiec J; Zbucki R; Winnicka M; Sawicki B; Nikolajuk A; Kaminski K; Mysliwiec P; Musial W; Bondyra Z; Walecki J; Gorska M Folia Histochem Cytobiol; 2007; 45(4):387-92. PubMed ID: 18165179 [TBL] [Abstract][Full Text] [Related]
3. Estrogens modulate RANKL-RANK/osteoprotegerin mediated interleukin-6 effect on thyrotoxicosis-related bone turnover in mice. Mysliwiec J; Zbucki R; Nikolajuk A; Mysliwiec P; Kaminski K; Bondyra Z; Dadan J; Gorska M; Winnicka MM Horm Metab Res; 2011 Apr; 43(4):236-40. PubMed ID: 21332025 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 and its considerable role in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in postmenopausal women. Mysliwiec J; Adamczyk M; Nikolajuk A; Gorska M Endokrynol Pol; 2011; 62(4):299-302. PubMed ID: 21879468 [TBL] [Abstract][Full Text] [Related]
5. Role of interleukin-6 on RANKL-RANK/osteoprotegerin system in hypothyroid ovariectomized mice. Mysliwiec J; Zbucki R; Nikolajuk A; Mysliwiec P; Taranta A; Kaminski K; Bondyra Z; Dadan J; Gorska M; Winnicka MM Folia Histochem Cytobiol; 2010 Dec; 48(4):549-54. PubMed ID: 21478097 [TBL] [Abstract][Full Text] [Related]
6. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688 [TBL] [Abstract][Full Text] [Related]
7. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202 [TBL] [Abstract][Full Text] [Related]
9. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477 [TBL] [Abstract][Full Text] [Related]
10. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum]. Uchida K; Nakanishi M; Yoh K Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484 [TBL] [Abstract][Full Text] [Related]
11. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Rissanen JP; Suominen MI; Peng Z; Halleen JM Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692 [TBL] [Abstract][Full Text] [Related]
13. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501 [TBL] [Abstract][Full Text] [Related]
14. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370 [TBL] [Abstract][Full Text] [Related]
15. Does methamphetamine affect bone metabolism? Tomita M; Katsuyama H; Watanabe Y; Okuyama T; Fushimi S; Ishikawa T; Nata M; Miyamoto O Toxicology; 2014 May; 319():63-8. PubMed ID: 24582730 [TBL] [Abstract][Full Text] [Related]
16. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. Alatalo SL; Peng Z; Janckila AJ; Kaija H; Vihko P; Vaananen HK; Halleen JM J Bone Miner Res; 2003 Jan; 18(1):134-9. PubMed ID: 12510815 [TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients. Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281 [TBL] [Abstract][Full Text] [Related]
18. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients. Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113 [TBL] [Abstract][Full Text] [Related]
19. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Halleen JM Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342 [TBL] [Abstract][Full Text] [Related]
20. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker]. Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]